Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
XXX (1) - Saccharomyces boulardii & Crohn's disease (CD)
Saccharomyces boulardii does not appear to have any beneficial effects for patients with CD in remission after steroid or salicylate therapies (1)
XXX (2) - Saccharomyces boulardii & Crohn’s disease (CD)
The trial observed a significant reduction in the frequency of bowel movements among the group treated with Saccharomyces boulardii (S.b.) By the tenth week, this group experienced an average of 3.3 ± 1.2 evacuations per day. Additionally, there was a significant decrease in the BEST Index, which dropped to 107 ± 85 (2)
[XXX (3) - Saccharomyces boulardii &…